Business Wire

B2Broker Seals European Presence with CySEC-Regulated Provider B2Prime

Share

B2Broker, a leading technology and liquidity provider within the Forex/CFDs and Digital Currency industries, has confirmed that it has expanded its global reach by establishing a presence in the heavily EU regulated Forex /CFDs market through B2Prime, a Cyprus based Financial Institution authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005172/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

B2Broker seals European presence with CySEC-regulated multi-asset liquidity provider B2Prime. (Graphic: Business Wire)

B2Broker now has a vested interest in B2Prime after fulfilling the necessary legal requirements for the required ownership changes. The new owners of B2Prime are Arthur Azizov, founder of B2Broker Group of Companies and Evgeniya Mykulyak, co-founder of B2Broker Group of Companies. Nick Chrysochos becomes the CEO of B2Prime. The move confirms the group’s commitment to providing its investment related services on a global scale through a Liquidity Provider regulated by one of the most well respected and recognised Financial Market Supervisory Authorities.

About B2Prime

B2Prime is a global regulated Prime of Prime (PoP) Multi-Asset Liquidity Provider for institutional and professional clients across the whole spectrum of the financial markets. Its core investment services consist of leveraged derivative products in CFDs (Forex, metals, commodities, shares, indices and cryptocurrencies).

B2Broker Group of Companies

B2Broker is a global brand with a solid reputation in the B2B sphere as one of the most in-demand technology and liquidity providers for Forex and crypto brokers, crypto exchanges and other financial services entities. The company offers a wide range of services including Crypto/Forex/CFD liquidity,Crypto/Forex Broker turnkey solutions, crypto payment processing (B2BinPay), MT4/5 white label solutions, B2Core (Trader’s Room), B2Trader (Matching Engine) and liquidity on over 800 trading instruments across the entire spectrum of assets.

Headquartered in Moscow, B2Broker has several years of operational experience with 10 offices in 8 countries across Russia, Europe, Asia and MENA. A total of 7 licences to its name including FCA, AEMI and Central Bank of Russia, allows B2Broker to serve clients across 50 countries, offering Forex liquidity distribution and a range of other services to the Forex, Crypto and Securities industries. The company has secured a large portfolio of well-known global clients in the financial services industry with plans to further increase company representation and visibility across the globe.

What the News Means For Clients

CySEC is Cyprus’ financial regulator which provides a framework within which the country’s licenced financial services firms are obliged to operate. As a CySEC regulated broker, B2Prime must adhere to the strictest financial market regulatory standards, including capital adequacy requirements, segregation of client funds and transparency of business operations.

Clients residing in the EU, UK and several other 3rd country jurisdictions can now be safely onboarded under the EU MiFID II regulatory standards. B2Broker can now expand its footprint in the European Union and provide clients with the opportunity to experience the organisation’s full product and service offering through an EU financial services brokerage licence, while positioning itself on an accelerated global growth path.

B2Broker Group of Companies CEO, Arthur Azizov, commented, “We are delighted that B2Prime has secured CySEC approval. The licence gives us the scope to provide institutional grade liquidity to clients in over 30 countries. Meanwhile, our clients will be able to benefit from an enhanced level of protection, safe in the knowledge that they have the backing of a world-leading, multi-regulated technology and liquidity provider. We expect that having now secured CySEC’s authorisation to provide our investment liquidity services, it will help us establish our place in this space as one of the strongest and most reliable organisations where clients can feel at ease when trading with us”.

B2Prime’s owner and Executive Director, Evgeniya Mykulyak, co-founder of B2Broker Group commented, “My vision is to make B2Prime one of the most solid and reliable financial services companies in the Forex space with a high standard of service provision being our key focus. I look forward to exploring the many new opportunities available to us in Europe and to welcoming new clients on board. Our efforts will include the introduction of new trading platforms for connection as well as the continued rollout of our Prime of Prime liquidity services. We are already building a strong liquidity provision network in the European market and have established relationships with major Prime Brokers. Furthermore, we plan to become a member of several exchanges, all in all, making B2Prime a major player in the financial services industry”.

B2Prime CEO, Nick Chrysochos added, “With Artur Azizov’s long experience and solid credentials in the Forex and Crypto space and Evgeniya Mykulyak’s deep industry know-how and clear vision for the company, we will be able to provide advanced, cutting-edge technology so that our clients can trade with the reassurance of knowing that their trading activities are managed by a reputable firm that adheres to the most stringent regulatory standards of CySEC”.

Final Word

BPrime has already opened the door to receiving new clients and can connect brokers via OneZero, MT5 and PrimeXM platforms to offer trading on 115 Forex pairs including 22 Crypto CFD pairs, Spot Metals, Indices and Spot Energies.

The latest licence acquisition is a part of B2Broker’s overall strategic plan to have a presence in all the major jurisdictions, focusing on the goal of becoming a global liquidity provider. The corresponding launch of commercial operations in Cyprus is also a testament to the company’s ongoing success and growth, where it will continue to provide some of the best liquidity and trading services in the industry.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rosemary Barnes
Head of PR
pr@b2broker.net
www.b2broker.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mandate of BaFin’s special commissioner at flatexDEGIRO terminated18.10.2024 17:25:00 CEST | Press Release

Mandate of BaFin’s special commissioner at flatexDEGIRO terminated The mandate of the BaFin’s special commissioner at flatexDEGIRO Bank AG (the “Company”) was terminated on September 30, 2024, following the successful elimination of the serious deficiencies identified in the 2022 special audit by the Company and a positive review by the special commissioner. flatexDEGIRO AG made this announcement on October 18, 2024, following a corresponding decision by the German Federal Financial Supervisory Authority (BaFin). Oliver Behrens, CEO of flatexDEGIRO, said: “We have realigned and sustainably strengthened our organizational structures and processes in constructive cooperation with BaFin and the special commissioner. We are thereby closing a regulatory chapter and again increase our focus on our customers and important growth projects. My special thanks go to all employees who, under the leadership of Steffen Jentsch, member of the bank's management board, have made it possible to reach th

Biological Lattice Industries (BLI) Secures $1.8 Million Pre-Seed Funding Led by Uni.Fund to Democratize Biofabrication18.10.2024 16:00:00 CEST | Press Release

Biological Lattice Industries Corp. (BLI), a leading innovator in biofabrication and life sciences R&D, today announced the successful closing of a $1.8 million pre-seed investment round led by Greek venture capital firm Uni.Fund. In conjunction with this funding announcement , BLI is introducing its first all-in-one solution for biofabrication: BioLoom™, BLI's advanced multi-tool 3D bioprinter and Loominus Studio™, its unified software platform designed to revolutionize biofabrication workflows. BLI, a US startup with R&D operations in Greece, aims to radically simplify biofabrication for the global R&D community by providing intelligent, automated tools that streamline the design, fabrication, and testing of biomaterials. Biomaterials are critical for a wide array of biological applications. The applications range from advanced 3D cell culture systems for human biology emulation to the next-generation of resorbable medical devices and drug delivery systems for tissue trauma repair. “

Gurobi Brings Decision Intelligence Summit to Amsterdam18.10.2024 15:00:00 CEST | Press Release

Gurobi Optimization, LLC, the leader in decision intelligence technology, is set to host the first annual EMEAI Decision Intelligence Summit (“Gurobi Summit”) at Amsterdam’s Capital C on November 5-6, 2024. Following the success of last month’s inaugural summit for the Americas in Las Vegas, the EMEAI Summit will bring together operations researchers, data scientists, and business leaders from across the region to explore the latest advancements in mathematical optimization and decision intelligence. The Gurobi Summit will feature special presentations from companies such as Accenture and ICRON. Several of the company’s partners—including Decide4AI, Decision Labs, LTPLabs, and ORMAE—will also be present to showcase their solutions and insights. The two-day event will be packed with informative presentations, exciting customer case studies, and interactive learning opportunities. Day 1 will feature keynotes, technical presentations, and panel discussions. Day 2 will be dedicated to hand

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting18.10.2024 14:00:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from October 18-22, 2024 in Philadelphia, Pennsylvania. Abstract A1187 — “Randomized, Placebo-Controlled, Phase 3 Trials of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor for Treatment of Acute Pain After Abdominoplasty or Bunionectomy” will be presented as an oral presentation on Sunday, October 20, during the “Best Abstract” session, which runs from 8:00-11:00 a.m. ET, as well as the Education session which runs on Monday, October 21, from 1:30-2:30 p.m. ET. Abstract A2074 — “A Phase 3, Single-Arm Study of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor For Treatment of Acute Pain From Surgical and Non-surgical Conditions” will be present

SLB Announces Third-Quarter 2024 Results18.10.2024 12:50:00 CEST | Press Release

SLB (NYSE: SLB) today announced results for the third quarter of 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241016795721/en/ The exterior of the SLB headquarters in Houston, Texas. (Photo: Business Wire) Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2024Jun. 30, 2024Sept. 30, 2023SequentialYear-on-yearRevenue $9,159 $9,139 $8,310 - 10% Income before taxes - GAAP basis $1,507 $1,421 $1,395 6% 8% Income before taxes margin - GAAP basis 16.5% 15.5% 16.8% 91 bps -33 bps Net income attributable to SLB - GAAP basis $1,186 $1,112 $1,123 7% 6% Diluted EPS - GAAP basis $0.83 $0.77 $0.78 8% 6% Adjusted EBITDA* $2,343 $2,288 $2,081 2% 13% Adjusted EBITDA margin* 25.6% 25.0% 25.0% 55 bps 54 bps Pretax segment operating income* $1,902 $1,854 $1,683 3% 13% Pretax segment operating margin* 20.8% 20.3% 20.3% 48 bps 51 bps Net income attributable to SLB, excluding charges & cr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye